On February 7, Ge Longhui Pharmaceutical (600513.SH) announced that on February 6, 2024, the company received a notice from Lianhuan Group, the controlling shareholder. Lianhuan Group increased its holdings of Lianhuan Pharmaceutical shares by 3,744,300 shares through centralized bidding transactions, accounting for 1.31% of the company's total share capital.
联环药业(600513.SH)：控股股东增持1.31%股份
Lianhuan Pharmaceutical (600513.SH): Controlling shareholder increased shareholding by 1.31%
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.